Home > Newsletters > FDAnews Device Daily Bulletin > St. Jude Occluder Misses Endpoint, Company Gets Predicted Form 483
FDAnews Device Daily Bulletin
Nov. 1, 2012 | Vol. 9 No. 215
St. Jude Occluder Misses Endpoint, Company Gets Predicted Form 483
St. Jude Medical announced Thursday that the company’s Amplatzer PFO Occluder has missed its primary endpoint in the RESPECT trial to evaluate the device’s success at reducing recurrent stroke risk. The trial was launched in 2003 and enrolled 980 patients at 69 centers. All patients had experienced strokes with no known cause before the trial commenced and were randomized to either Amplatzer or a medical management control arm.
Devices & Diagnostics Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.